GE HealthCare has launched an AI Innovation Lab to advance early-stage artificial intelligence concepts in healthcare.
The lab aims to integrate AI into medical devices and develop applications for clinical decision-making.
Cloud technology is a key investment for GE HealthCare, providing computational power for AI development.
One project from the lab is the Health Companion, which uses agentic AI to replicate the problem-solving abilities of a medical team.
GE HealthCare is collaborating with Emory University's Winship Cancer Institute to use AI to predict the recurrence of triple-negative breast cancer.
GE HealthCare has also submitted an application to the FDA for AI-based fetal heart rate interpretation.
The company has a strong market position and generated sales of $19.52 billion in the last twelve months.
Analysts are optimistic about GE HealthCare's growth potential in AI and digital health solutions.
They recently unveiled CareIntellect for Oncology, an AI-powered cloud application for cancer treatment data.
The FDA has approved Flyrcado, a diagnostic drug for coronary artery disease.
GE HealthCare is well-positioned to capitalize on the demand for advanced healthcare solutions and is committed to improving diagnostic accuracy and patient care.